Tutti gli studi
ReclutamentoFASE4INTERVENTISTICO

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

This research study is investigating a new medicine, mirikizumab, for adults aged 18 to 75 who have Crohn's disease. Crohn's disease is a long-term condition that causes inflammation in the digestive system. The study wants to see if mirikizumab can help heal the deeper layers of the bowel wall, not just the surface lining. This is called 'transmural healing'. Researchers will use special scans like MRI to check for this healing. The goal is to understand if this treatment, given either through a drip or as an injection under the skin, can improve the condition more effectively for people with active Crohn's symptoms. This is a Phase 4 study, meaning the medicine has already been approved but researchers are still gathering more information about its effects.

A colpo d'occhio

Stato
Reclutamento
Fase
FASE4
Sponsor
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Obiettivo di iscrizione
75
Inizio
11 Maggio 2026
Completamento stimato
01 Nov 2028

Di cosa tratta questo studio?

Crohn's disease is a condition where parts of your digestive system become inflamed. This can cause symptoms like tummy pain and needing to go to the toilet a lot. Medicines for Crohn's disease often aim to reduce these symptoms and heal the surface lining of your bowel. However, inflammation can sometimes go deeper into the bowel wall. This study is looking at a new medicine called mirikizumab, and specifically whether it can help heal these deeper layers of the bowel, which is known as 'transmural healing'.

Recognising and treating this deeper healing is important because it might lead to better long-term health for people with Crohn's. The study will use special scans, like MRI, to see if mirikizumab helps to reduce this deeper inflammation and encourages healing within the bowel wall. Doctors want to understand if this approach could make a real difference to how well people with Crohn's disease manage their condition.

Mirikizumab is already an approved medicine, but this particular study is a 'Phase 4' trial. This means that while the medicine is available, researchers are still gathering more detailed information about its effects, especially concerning this specific type of healing in Crohn's disease. Understanding transmural healing better could help doctors provide more targeted and effective treatments in the future.

Punti chiave

  • This study is for adults with active Crohn's disease.
  • It tests a medicine called mirikizumab to see if it heals the deep layers of the bowel.
  • MRI scans will be used to check for internal healing.
  • You will receive careful medical monitoring if you participate.
  • Puoi ritirarti dallo studio in qualsiasi momento.

Chi può essere idoneo?

To be part of this study, you need to be an adult between 18 and 75 years old and have been diagnosed with Crohn's disease. You should also be experiencing symptoms, such as needing to go to the toilet more than three times a day or having tummy pain. Doctors will also check with a special MRI scan to see if you have inflammation deep within your bowel wall.

There are some reasons why you might not be able to join. For example, if you've recently used certain other powerful medicines for Crohn's, or if you have specific other health conditions like an active infection, a history of certain surgeries on your bowel, or if you are pregnant or breastfeeding. You also can't have certain medical conditions that would make an MRI scan unsafe, or lack health insurance.

If you're unsure whether you fit the criteria, it's always best to discuss it with your doctor or the study team. They can help you understand all the details and decide if this study might be right for you.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you 18 to 75 years old?
  2. Do you have Crohn's disease and currently have symptoms like tummy pain or frequent bowel movements?
  3. Have you *not* had specific powerful treatments for Crohn's in the past or very recently?
  4. Sei in grado di sottoporti a una risonanza magnetica?
  5. Non sei incinta o stai allattando?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part in this study, you would first have a full medical check-up to make sure the study is suitable for you. You would then receive the study medicine, mirikizumab, which could be given either through a drip into your arm or as an injection under your skin, depending on what the study team advises. You would have regular visits to the clinic for medical examinations, blood tests, and to discuss any symptoms or side effects you might be experiencing.

Crucially, you would also have MRI scans at different points during the study. These scans help doctors see if your bowel is healing on the inside. You'll be asked to keep a record of your symptoms. The total length of your participation in the study would be explained to you in detail by the study team.

Rischi e benefici potenziali

Taking part in a study like this could offer potential benefits, such as receiving a new or different treatment for your Crohn's disease and having very close monitoring of your health by a specialist team. However, there are also potential risks, as with any medicine. Mirikizumab might cause side effects, and you would need to attend regular appointments and have scans. All the possible risks and side effects will be explained to you fully before you decide to join. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Luoghi (6)

  • CHU de Brest - Hôpital de la Cavale Blanche
    Codice postale verificato
    Brest, Francia· Non ancora in fase di reclutamento
  • CHU de Clermont Ferrand - Hôpital d'Estaing
    Codice postale verificato
    Clermont-Ferrand, France· Reclutamento
  • CHU de Nîmes Carémeau
    Codice postale verificato
    Nîmes, Francia· Non ancora in fase di reclutamento
  • Institut Mutualiste Monsouris
    Codice postale verificato
    Parigi, Francia· Non ancora in fase di reclutamento
  • CHU de Toulouse - Hôpital Rangueil
    Codice postale verificato
    Tolosa, Francia· Non ancora in fase di reclutamento
  • CH de Valence
    Codice postale verificato
    Valence, Francia· Non ancora in fase di reclutamento

Domande comuni

Che cos'è la malattia di Crohn?

Crohn's disease is a condition that causes swelling and irritation (inflammation) in your digestive system, which can lead to tummy pain, diarrhoea, and tiredness.

What does 'transmural healing' mean?

It means the medicine helps to heal the inflammation deep within the wall of your bowel, not just on the inside surface. This deeper healing is thought to be very beneficial for Crohn's disease.

What is mirikizumab?

Mirikizumab is a specific type of medicine used to treat inflammatory conditions like Crohn's disease. It works by targeting certain immune responses in your body.

Will I get the medicine through a drip or an injection?

The study is looking at both ways of giving mirikizumab – either into a vein (like a drip) or as an injection under the skin. The study team will tell you which method applies to you.

Posso abbandonare lo studio se cambio idea?

Yes, you can leave the study at any time without having to give a reason. This won't affect your regular medical care.

Come saperne di più

Julie MUSSOT

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "Efficacy of MIrikizumab to Achieve Transmural Healing in pat…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.